EP3894858A1 - Verfahren für die analyse einer blutprobe eines menschen auf eine tuberkuloseerkrankung durch detektion von tb-antigen stimulierter cd154-expression in kombination mit cd38, ki-67 oder hla-dr - Google Patents
Verfahren für die analyse einer blutprobe eines menschen auf eine tuberkuloseerkrankung durch detektion von tb-antigen stimulierter cd154-expression in kombination mit cd38, ki-67 oder hla-drInfo
- Publication number
- EP3894858A1 EP3894858A1 EP19821062.7A EP19821062A EP3894858A1 EP 3894858 A1 EP3894858 A1 EP 3894858A1 EP 19821062 A EP19821062 A EP 19821062A EP 3894858 A1 EP3894858 A1 EP 3894858A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- marker
- status
- tuberculosis
- marking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 55
- 210000004369 blood Anatomy 0.000 title claims abstract description 32
- 239000008280 blood Substances 0.000 title claims abstract description 32
- 239000000427 antigen Substances 0.000 title claims abstract description 21
- 102000036639 antigens Human genes 0.000 title claims abstract description 19
- 108091007433 antigens Proteins 0.000 title claims abstract description 19
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 9
- 238000001514 detection method Methods 0.000 title claims description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 title claims description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 title claims description 4
- 239000003550 marker Substances 0.000 claims abstract description 80
- 210000004027 cell Anatomy 0.000 claims abstract description 61
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 38
- 230000000638 stimulation Effects 0.000 claims abstract description 24
- 241000894006 Bacteria Species 0.000 claims abstract description 18
- 230000004913 activation Effects 0.000 claims abstract description 13
- 208000036981 active tuberculosis Diseases 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 8
- 238000011156 evaluation Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 2
- 230000008823 permeabilization Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 abstract description 3
- 238000002372 labelling Methods 0.000 abstract 5
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 206010065048 Latent tuberculosis Diseases 0.000 description 9
- 239000007858 starting material Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 3
- 208000033353 latent tuberculosis infection Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Definitions
- the present invention relates to a method for the analysis of a human blood sample for an active tuberculosis infection (ATBI).
- ATBI active tuberculosis infection
- Tuberculosis is a chronic infection caused by mycobacteria from the Mycobacterium tuberculosis complex (MTBC).
- MTBC Mycobacterium tuberculosis complex
- tuberculosis infections in humans are caused by M. tuberculosis sensu stricto and M. africanum.
- Infection with tuberculosis bacteria only leads to tuberculosis or active tuberculosis infection in humans in approx. 10% of cases.
- LTBI latent tuberculosis infection
- tuberculosis bacteria remain in humans. A transition from a latent to an active tuberculosis infection and thus an illness is possible.
- tuberculosis In order to select a tuberculosis therapy or to verify the success of the therapy, the clearest possible proof of a tuberculosis disease is necessary.
- the detection of tuberculosis is carried out in a wide variety of ways. In principle, the detection of a tuberculosis infection is possible on the basis of blood samples. Here the reaction of the immune system to tuberculosis antigens is examined. If there is a reaction, it can be concluded that the patient in question is infected with tuberculosis bacteria. However, blood tests currently used cannot be used to determine whether the person in question is only latently infected with tuberculosis or whether there is an active tuberculosis disease.
- a method of analyzing a human blood sample for a tuberculosis disease is based on examining an immune response against tuberculosis bacteria. Such a process has the following steps:
- a tuberculosis infection in the blood sample of a human is to be detected and classified here too.
- cells from a blood sample for example in the form of isolated mononuclear cells or whole blood
- the starting material can thus be obtained minimally invasively in the form of a peripheral venipuncture. Biopsies and time-consuming cultivation of tuberculosis bacteria are eliminated.
- a key concept of the present invention is based on the analysis of T cells (for example CD4 + T cells) which are part of the cells made available.
- T cells for example CD4 + T cells
- the cells made available are stimulated with tuberculosis antigens.
- Structures which are part of bacteria of the Mycobacterium tuberculosis complex (MTBC), for example ESAT-6 / CFP-10 peptides or purified protein derivative (PPD) can be used as tuberculosis antigens.
- the T cells that respond to stimulation with tuberculosis antigens are labeled and characterized.
- the marking is made possible by the induction of the at least one presence marker on these T cells.
- the method can be described as a two-stage process.
- tuberculosis-antigen-specific T cells are identified using the at least one presence marker. These cells are found in both latent and actively infected patients with tuberculosis.
- it is examined whether the cells which carry the at least one presence marker also carry one of the status markers. This at least one status marker allows a conclusion to be drawn about the activation status of the tuberculosis-antigen-specific cells, as cells with presence markers.
- the presence marker can be used to draw conclusions about the presence of tuberculosis bacteria and the status marker, the status, that is to say the distinction between latent and active manifestation of the tuberculosis infection.
- the frequency of the presence markers and T cell-bearing status markers or the marking strength of the status marker on the T-cell bearing presence marker is determined and compared with a combination limit value.
- Combination limit values can be defined as a clear limit value or as a transition range, as will be explained later. In other words, in the set of cells made available, marked cells can now be recognized and evaluated, which carry a combination of at least one presence marker and at least one status marker.
- the number of such cells with a combined marking or the marking strength of a status marker as a measure of its frequency on the cells which also carry the at least one status marker can now be normalized to a total number of cells and compared with a combination limit. If the number of combined labeled cells exceeds the Combination limit, an active tuberculosis infection can be assumed, in particular with a certain probability.
- a presence marker and a status marker are proteins on a subgroup of the cells made available which have specific correlations with the parameters to be analyzed.
- the frequency of the cells that carry the presence marker after stimulation with tuberculosis antigens correlates with the frequency of tuberculosis-specific T cells in the patient's blood.
- a presence marker must meet two conditions in particular: After in vitro stimulation, it should, if possible, only be formed by cells which specifically recognize the stimulant (here: tuberculosis antigen).
- the duration that the presence marker can be found on the cells after stimulation should be limited, so that the method does not erroneously identify cells that were activated before in vitro stimulation.
- tuberculosis antigens allow the analysis of tuberculosis-specific T cells in the cells made available.
- the stimulation takes place over a defined period of 1 to 72 hours, of which in particular 1 to 48 hours, of which in particular 1 to 24 hours, of which in particular 1 to 12 hours, of which in particular 1 to 7 hours, of which in particular 4 to 6 hours.
- the stimulation and the associated induction of the at least one presence marker therefore make it possible to recognize the cells and distinguish them from other cells which are specific for tuberculosis antigens.
- Live bacteria, dead bacteria or, in particular, fragments or synthesized structures that resemble structures of tuberculosis bacteria e.g. lysates, protein extracts, purified proteins, protein mixtures, recombinantly produced proteins or protein fragments, peptides or nucleic acid sequences
- tuberculosis bacteria are often closed in an encapsulated area of the body and in this state only have a limited interaction with the patient's adaptive immune system (including T cells).
- T cells including T cells
- the activation of the T cells by this contact leads to them starting to form activation markers, which are sometimes used as status markers.
- the analysis of the marking of the at least one status marker in a quantitative and / or qualitative manner allows a statement to be made regarding the distinction between latent and active tuberculosis. It should also be pointed out that the status markers on the T cells already arise in the body and that no separate stimulation is necessary for this. The status markers differ from the at least one presence marker.
- the blood sample is evaluated in a method according to the invention.
- a comparison of a defined total cell population to the cells contained therein, which have the at least one presence marker and one or more of the status markers, is carried out in the marking result.
- a combination limit value which indicates the relative frequency of the T cells that carry the presence marker and one of the status markers or the marking strength of one of the status markers, an active tuberculosis disease can now be assumed above the limit value.
- the at least one presence marker specifically indicates the contact of the cells with at least one tuberculosis bacterial antigen in humans.
- the presence markers are expressed on the T cells which are specific against tuberculosis antigens.
- tuberculosis bacteria produce corresponding biological, chemical and / or biochemical reactions in the body. This is based in particular on a corresponding reaction of the human immune system.
- the presence marker is stimulated specifically and without a second indication only in T cells, which in turn are specific for a tuberculosis infection. This is the case with a stimulation duration of 1 to 72 hours, of which in particular 1 to 48 hours, of which in particular 1 to 24 hours, of which in particular 1 to 12 hours, of which in particular 1 to 7 hours, of which in particular 4-6 hours.
- the at least one status marker has at least one activity parameter for the activation status of the T cells in the blood sample.
- the activation status of the T cells in humans they have corresponding status markers on the surface.
- Activated T cells can be distinguished from other T cells.
- the activation and thus the presence of a status marker is not limited to a tuberculosis infection. In combination with the at least one presence maker, however, the combination limit can be used to restrict tuberculosis infection.
- the status marker has at least one of the following configurations:
- the at least one status marker is changed by in vivo stimulation of the specific T cells
- the list above is a non-exhaustive list.
- the quantitative correlation allows an activity parameter to also provide a quantitative and thus a probability statement as to whether it is active or latent tuberculosis.
- the activity parameter is mapped in the combination limit.
- a stability of the activity parameter for the duration of the test can be used to provide a sample that is easier to handle and, in particular, also to provide transport between the sampling location and the analysis location. Since the status marker is not generated by the patient's own stimulation in the method, but is already in the blood sample when the blood sample is taken, this temporal stability ensures greater flexibility in the use of the method according to the invention.
- a limit value is defined for the combination limit value, when it is exceeded an active tuberculosis disease is recognized.
- This limit value is preferably equipped with a safety margin in order to have the corresponding safety for the subsequent treatment for a positive test result.
- the combination limit has at least two limit values with different probabilities for the detection of an active tuberculosis disease. This means that not only can a distinction be made between a negative and a positive test result, but different probabilities can be assumed in particular in the positive result. If the test result is between the two limit values, for example, the likelihood of tuberculosis is lower than if both limit values are exceeded. At least gradually, a quantitative statement is possible regarding the probability of the test procedure.
- a further advantage can be if, in a method according to the invention, the marking of the at least one presence marker and the at least one status marker is carried out in parallel at least in sections.
- the marking preferably takes place simultaneously or essentially simultaneously. It is irrelevant whether a common marking mixture should be used for marking both markers or separate marking agents.
- the design of this marking step, which is parallel at least in sections, further reduces the time required for a method according to the invention and the corresponding costs.
- the at least one presence marker and the at least one status marker are colored with the same marker mixture. This is particularly the case in combination with the embodiment according to the preceding paragraph.
- At least some of the cells made available from the blood sample are stimulated and / or at least some of the cells made available from the blood sample remain unstimulated.
- the stimulation of the blood sample is in particular biological, chemical and / or biochemical. In a qualitative and / or quantitative manner, it can provide reinforcement or simplification in the analysis according to the invention.
- Such a negative control is combined in particular with a positive control.
- a further advantage can be achieved if, in a method according to the invention, the cells are made available from a blood sample with peripheral blood. This further reduces the invasiveness of the preliminary procedure necessary for the blood sample.
- the blood sample can be made available quickly and easily and can serve as a starting point for a method according to the invention.
- a further advantage can be achieved if, in a method according to the invention, the marking steps are carried out free of permeabilization on the cells made available. It is therefore not necessary to loosen or open the cell walls of the cells made available, so that the preparation effort when carrying out a method according to the invention can be reduced. The time required for the analysis can also be reduced. In this way, a further simplification and reduction of the complexity can be made available for a method according to the invention.
- Fig. 3 shows an embodiment in the evaluation of a presence marker
- Fig. 4 shows a further embodiment in the evaluation of an inventive
- FIG. 1 schematically shows how cells (110) made available from a peripheral blood sample 100 are stimulated with a stimulation agent ST.
- Markers FM either in the form of a mixture of markers or different FM markers, can be used to mark presence markers AM and status markers SM on / in the cells 110 provided.
- this marking is evaluated in an evaluation unit 200 so that the combination limit value KG can be analyzed qualitatively and / or quantitatively.
- FIG. 3 and 4 schematically show how the corresponding limits for the presence marker AM and the status marker SM can be designed.
- Three blood sample analysis results can be seen in FIG. 3. While the left analysis is a combination limit value KG with a single limit value, FIG. 4 shows a combination limit value KG with two individual partial limit values. The combination of the two markers AM and SM is above the combination limit value KG in the right sample of FIG. 3, so that the presence of an active tuberculosis disease can be affirmed here. The left sample accordingly designates a negative test since the combination of the two markers AM and SM is below the combination limit value KG.
- FIG. 2 shows a further embodiment of a method according to the invention, in which the cells 110 made available are divided. While for further processing and marking with the marking means FM there is a stimulation with the aid of a stimulation means ST, a negative sample is previously branched off from the cells 110 provided.
- the present invention is described only by way of examples. Of course, if technically meaningful, individual features of the embodiments can be freely combined with one another without departing from the scope of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102018131696.8A DE102018131696B4 (de) | 2018-12-11 | 2018-12-11 | Verfahren für die Analyse einer Blutprobe eines Menschen auf eine Tuberkuloseerkrankung |
PCT/EP2019/084392 WO2020120459A1 (de) | 2018-12-11 | 2019-12-10 | Verfahren für die analyse einer blutprobe eines menschen auf eine tuberkuloseerkrankung durch detektion von tb-antigen stimulierter cd154-expression in kombination mit cd38, ki-67 oder hla-dr |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3894858A1 true EP3894858A1 (de) | 2021-10-20 |
Family
ID=68887408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19821062.7A Pending EP3894858A1 (de) | 2018-12-11 | 2019-12-10 | Verfahren für die analyse einer blutprobe eines menschen auf eine tuberkuloseerkrankung durch detektion von tb-antigen stimulierter cd154-expression in kombination mit cd38, ki-67 oder hla-dr |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3894858A1 (de) |
DE (1) | DE102018131696B4 (de) |
WO (1) | WO2020120459A1 (de) |
ZA (1) | ZA202103675B (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102021203480A1 (de) | 2021-04-08 | 2022-10-13 | Labor Berlin - Charité Vivantes Services GmbH | Verfahren für die Analyse einer Blutprobe auf eine Erkrankung |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2950436T3 (es) * | 2016-12-14 | 2023-10-10 | Becton Dickinson Co | Métodos y composiciones para obtener una valoración de tuberculosis en un sujeto |
-
2018
- 2018-12-11 DE DE102018131696.8A patent/DE102018131696B4/de active Active
-
2019
- 2019-12-10 WO PCT/EP2019/084392 patent/WO2020120459A1/de active Search and Examination
- 2019-12-10 EP EP19821062.7A patent/EP3894858A1/de active Pending
-
2021
- 2021-05-28 ZA ZA2021/03675A patent/ZA202103675B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020120459A1 (de) | 2020-06-18 |
DE102018131696B4 (de) | 2020-09-17 |
ZA202103675B (en) | 2024-04-24 |
DE102018131696A1 (de) | 2020-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE102009033368B4 (de) | Massenspektrometrische Sepsisdiagnose | |
DE102007058516B4 (de) | Identifizierung von Erregern in Körperflüssigkeiten | |
EP1527407A2 (de) | Verfahren sowie computerprogramm mit programmcode-mitteln und computerprogramm-produkt zur analyse einer wirksamkeit eines pharmazeutischen präparats | |
DE102009032649A1 (de) | Massenspektrometrische Identifizierung von Mikroben nach Unterarten | |
DE102010033105B4 (de) | Massenspektrometrische Sepsisdiagnose ohne Blutkultur | |
DE2632478A1 (de) | Verfahren zur erfassung und trennung von antigenen und antikoerperchen im blut und in anderen proben | |
DE10112470B4 (de) | Verfahren zur Proben-Identifizierung bei einem Säugetier sowie Kit zur Durchführung dieses Verfahrens | |
EP1869450A2 (de) | Reagenz und verfahren zur verhinderung der zeitabhängigen rna-expression in biologischen zellen | |
EP3344781A1 (de) | Verwendung von im blutserum oder blutplasma zirkulierenden micrornas zur identifikation biopsiepflichtiger patienten und als marker zur differentialdiagnose einzelner nicht-ischämischer kardiomyopathien oder speichererkrankungen des herzens | |
EP0957359B1 (de) | ELISPOT-Verfahren zur Quantifizierung der Aktivität von menschlichen und tierischen Zellen, zur insbesondere Blutzellen | |
DE102018131696B4 (de) | Verfahren für die Analyse einer Blutprobe eines Menschen auf eine Tuberkuloseerkrankung | |
DE102013109065A1 (de) | Anordnung zum schnellen Diagnostizieren der Tuberkulose und zum Testen der pharmazeutischen Wirkung | |
DE102021203480A1 (de) | Verfahren für die Analyse einer Blutprobe auf eine Erkrankung | |
AT409382B (de) | Verfahren zur detektion, unterscheidung und quantifizierung von freien und eingekapselten nukleinsäuren in einer probe | |
EP1430309A2 (de) | Teststreifen für den nachweis von prionproteinen | |
DE10349162A1 (de) | Schnelltest zur Diagnose der Alzheimerschen Erkrankung | |
EP3322817B1 (de) | Oligonucleotide und deren verwendung | |
EP1984740B1 (de) | Probensammelverfahren | |
DE60116772T2 (de) | Verfahren zum anonymen registrieren, speichern und verwenden von körpermaterial und/oder davon abgeleiteter information | |
EP2758785B1 (de) | Verfahren zum überprüfen der selbstheilung durch das immunsystem eines mit humanen papillomviren infizierten probanden | |
DE102009046128A1 (de) | Nicht-invasives Screeningverfahren für Wirkstoffe gegen Hautalterung | |
WO2007028380A1 (de) | Funktioneller in vitro immunassay | |
DE102015216521B3 (de) | Verwendung spezifischer Gene zur diagnostischen Abgrenzung einer eosinophilen Myokarditis von anderen fulminanten entzündlichen Herzmuskelerkrankungen | |
WO2009147081A1 (de) | Interventionsvorrichtung zur sammlung von biologischem material und verfahren zur ihrer herstellung | |
DE102015206444B3 (de) | Verfahren zum Erkennen von Mikroorganismen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210616 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CHARITE - UNIVERSITAETSMEDIZIN BERLIN KOERPERSCHAFT DES OEFFENTLICHEN RECHTS Owner name: LABOR BERLIN- CHARITE VIVANTES SERVICES GMBH |